Curated News
By: NewsRamp Editorial Staff
May 01, 2026

Helus Pharma Corrects Release on TARA Mind Partnership for MDD Trial

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Helus Pharma's Phase 3 HLP003 for MDD with Breakthrough Therapy status offers a first-mover advantage in the growing psychedelic therapeutics market.
  • Helus Pharma corrects its April 28 release, clarifying TARA Mind partnership details for Phase 3 recruitment of HLP003 in major depressive disorder.
  • Helus Pharma's novel serotonergic agonists aim to provide durable mental health improvements, addressing the large unmet need in depression and anxiety.
  • Helus Pharma's HLP003 targets major depressive disorder and aligns with a recent executive order advancing mental health treatments.

Impact - Why it Matters

This news matters because it highlights Helus Pharma's strategic correction to ensure accuracy in its communications about a partnership that could accelerate the development of a breakthrough treatment for major depressive disorder. For patients and veterans suffering from depression, the HLP003 program offers hope for a novel therapy that promotes neuroplasticity. The alignment with a recent executive order also signals government support for innovative mental health treatments, potentially expediting regulatory processes and broadening access to care. Investors should note the company's commitment to transparency and its progression into Phase 3 trials, which are critical steps toward market approval.

Summary

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company formerly known as Cybin Inc., has issued a correction to its April 28, 2026 press release regarding its partnership with TARA Mind. The correction removes references to Veterans Exploring Treatment Solutions from earlier paragraphs while reaffirming the collaboration's alignment with a recent executive order aimed at advancing mental health treatments and clinical research participation. The partnership supports Phase 3 recruitment for Helus Pharma's HLP003 program in major depressive disorder and expands outreach in veteran communities. Helus Pharma is developing novel serotonergic agonists (NSAs) designed to promote neuroplasticity and address unmet needs in depression, anxiety, and other mental health conditions.

Helus Pharma's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder. The company operates in Canada, the United States, the United Kingdom, and Ireland. The correction ensures accuracy in messaging as the company continues to leverage its partnership with TARA Mind to recruit veterans and align with government initiatives. For the full press release, visit https://ibn.fm/re8HL.

InvestorWire, a specialized communications platform within the IBN Dynamic Brand Portfolio, distributed this news. InvestorWire offers wire-grade press release syndication, editorial syndication to over 5,000 outlets, enhanced press release services, and social media distribution to millions of followers. Helus Pharma invites investors and the public to follow its progress on its newsroom at https://ibn.fm/HELP and learn more at www.helus.com.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma Corrects Release on TARA Mind Partnership for MDD Trial

blockchain registration record for this content.